Barriers to initiate buprenorphine and methadone for opioid use disorder treatment with postdischarge treatment linkage

Abstract

AbstractBackgroundHospitals are an essential site of care for people with opioid use disorder (OUD). Buprenorphine and methadone are underutilized in the hospital.ObjectivesCharacterize barriers to in‐hospital buprenorphine or methadone initiation to inform implementation strategies to increase OUD treatment provision.Design, Settings, and ParticipantsSurvey of hospital‐based clinicians' perceptions of OUD treatment from 12 hospitals conducted between June 2022 and August 2022.MeasuresSurvey questions were grouped into six domains: (1) evidence to treat OUD, (2) hospital processes to treat OUD, (3) buprenorphine or methadone initiation, (4) clinical practices to treat OUD, (5) leadership prioritization of OUD treatment, and (6) job satisfaction. Likert responses were dichotomized and associations between “readiness” to initiate buprenorphine or methadone and each domain were assessed.ResultsOf 160 respondents (60% response rate), 72 (45%) reported higher readiness to initiate buprenorphine compared to methadone, 55 (34%). Respondents with higher readiness to initiate medications for OUD were more likely to perceive that evidence supports the use of buprenorphine and methadone to treat OUD (p < .001), to perceive fewer barriers to treat OUD (p < .001), to incorporate OUD treatment into their clinical practice (p < .001), to perceive leadership support for OUD treatment (p < .007), and to have great job satisfaction (p < .04). Clinicians reported that OUD treatment protocols with treatment linkage, increased education, and addiction specialist support would facilitate OUD treatment provision.ConclusionInterventions that incorporate protocols to initiate medications for OUD, include addiction specialist support and education, and ensure postdischarge OUD treatment linkage could facilitate hospital‐based OUD treatment provision.